![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto, Japan (H.H., T.K., N.U., K.I.); Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan (H.M., K.Y., S.Y.); Biotechnology Research Center, Faculty of Engineering, Toyama Prefectural University, Toyama, Japan (M.K., T.S.); and Laboratory of Nutrition, Koshien University, Nishinomiya, Japan (M.O.)
Our previous studies revealed the species-based difference of CYP24A1-dependent vitamin D metabolism. Although human CYP24A1 catalyzes both C-23 and C-24 oxidation pathways, rat CYP24A1 shows almost no C-23 oxidation pathway. We tried to identify amino acid residues that cause the species-based difference by site-directed mutagenesis. In the putative substrate-binding regions, amino acid residue of rat CYP24A1 was converted to the corresponding residue of human CYP24A1. Among eight mutants examined, T416M and I500T showed C-23 oxidation pathway. In addition, the mutant I500F showed quite a different metabolism of 1
,25-dihydroxyvitamin D3 [1
,25(OH)2D3] from both human and rat CYP24A1. These results strongly suggest that the amino acid residues at positions 416 and 500 play a crucial role in substrate binding and greatly affect substrate orientation. A three-dimensional model of CYP24A1 indicated that the A-ring and triene part of 1
,25(OH)2D3 could be located close to amino acid residues at positions 416 and 500, respectively. Our findings provide useful information for the development of new vitamin D analogs for clinical use.
Address correspondence to: Toshiyuki Sakaki, Biotechnology Research Center, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama 939-0398, Japan. E-mail: tsakaki{at}pu-toyama.ac.jp
This article has been cited by other articles:
![]() |
N. Urushino, S. Nakabayashi, M. A. Arai, A. Kittaka, T. C. Chen, K. Yamamoto, K. Hayashi, S. Kato, M. Ohta, M. Kamakura, et al. Kinetic Studies of 25-Hydroxy-19-nor-vitamin D3 and 1{alpha},25-Dihydroxy-19-nor-vitamin D3 Hydroxylation by CYP27B1 and CYP24A1 Drug Metab. Dispos., September 1, 2007; 35(9): 1482 - 1488. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Prosser, M. Kaufmann, B. O'Leary, V. Byford, and G. Jones Single A326G mutation converts human CYP24A1 from 25-OH-D3-24-hydroxylase into -23-hydroxylase, generating 1{alpha},25-(OH)2D3-26,23-lactone PNAS, July 31, 2007; 104(31): 12673 - 12678. [Abstract] [Full Text] [PDF] |
||||